OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) (NYSE:TAK) heeft vandaag aangekondigd dat het zijn Corporate Governance Report heeft ingediend bij de Tokyo Stock Exchange (“TSE”) in overeenstemming met met de regelgeving voor TSE-beursgenoteerde bedrijven. Het rapport is toegankelijk op de website van Takeda op: https://www.takeda.com/who-we-are/corporate-governance/.

Dit rapport is opgesteld op basis van de principes van de Corporate Governance Code zoals van kracht vanaf 1 juni 2018. Takeda zal tegen het einde een herzien Corporate Governance Rapport indienen op basis van de Corporate Governance Code zoals die van kracht is vanaf 11 juni 2021 tot eind december 2021.

Het meest recente Corporate Governance-rapport van Takeda is te vinden op de site voor het vrijgeven van informatie die wordt beheerd door de Japan Exchange Group, die bestaat uit de TSE en andere beurzen in Japan op:

https://www2.tse.or.jp/tseHpFront/CGK020010Action.do?Show=Show

Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange

OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) (NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.

This report is prepared based on the principles of the Corporate Governance Code as in effect as of June 1, 2018. Takeda will submit a revised Corporate Governance Report based on the Corporate Governance Code as in effect as of June 11, 2021, by the end of December 2021.

Takeda’s latest Corporate Governance Report can be found at the information disclosure site operated by the Japan Exchange Group which consists of the TSE and other exchanges in Japan at:

https://www2.tse.or.jp/tseHpFront/CGK020010Action.do?Show=Show

Takeda also furnished the English version of the Corporate Governance Report with the U.S. Securities and Exchange Commission (the “SEC”), available at www.sec.gov.

As for the general information about the Corporate Governance Report, please refer to the Japan Exchange Group website at: https://www.jpx.co.jp/english/equities/listing/cg/01.html.

Additionally, Takeda’s corporate governance policy as well as overall Environmental, Social and Governance information is explained in detail in its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. This report can be accessed on Takeda’s website at: https://air.takeda.com

*TSE’s Securities Listing Regulations [Rule 419].

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005332/en/

Contacts

Media Contacts:
Japanese media
Ryoko Matsumoto

ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414

Media Outside Japan
Christina Beckerman

christina.beckerman@takeda.com
+1 908-581-4133